INDUSTRY × Lymphoma × Head & Neck × Clear all
NCT05366881 2026-01-20

CAMPERR

Adela, Inc

Recruiting
7,000 enrolled
NCT06022029 2025-12-24

ON-5001

OncoNano Medicine, Inc.

Phase 1 Recruiting
168 enrolled
NCT05179824 2025-05-06

Tempus Priority Study: A Pan-tumor Observational Study

Tempus AI

Active not recruiting
1,000 enrolled
NCT03098589 2025-03-30

Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL)

Celgene

Completed
1,149 enrolled
NCT06583395 2024-11-01

QUANTUM

VitaMed Research LLC

Enrolling by invitation
3,000 enrolled
NCT05635266 2024-05-07

Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives

Sanguine Biosciences

Recruiting
20,000 enrolled
NCT03841110 2023-05-01

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

Fate Therapeutics

Phase 1 Completed
37 enrolled
NCT02178722 2022-02-14

Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers

Incyte Corporation

Phase 1/2 Completed
444 enrolled 19 charts
NCT02223052 2020-05-12

Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies

Celgene

Phase 1 Completed
89 enrolled
NCT02576665 2020-02-07

A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)

Tocagen Inc.

Phase 1 Terminated
21 enrolled
NCT00896454 2018-10-17

Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium

Amgen

Phase 2 Completed
33 enrolled 22 charts
NCT00413075 2015-07-08

Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma

Valerio Therapeutics

Phase 1 Completed
121 enrolled
NCT00496860 2013-07-22

Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies

Altor BioScience

Phase 1 Completed
26 enrolled 13 charts